纠正胶质母细胞瘤的药物开发模式需要进行系列组织采样。
Correcting the drug development paradigm for glioblastoma requires serial tissue sampling.
作者信息
Singh Kirit, Hotchkiss Kelly M, Parney Ian F, De Groot John, Sahebjam Solmaz, Sanai Nader, Platten Michael, Galanis Evanthia, Lim Michael, Wen Patrick Y, Minniti Giuseppe, Colman Howard, Cloughesy Timothy F, Mehta Minesh P, Geurts Marjolein, Arrillaga-Romany Isabel, Desjardins Annick, Tanner Kirk, Short Susan, Arons David, Duke Elizabeth, Wick Wolfgang, Bagley Stephen J, Ashley David M, Kumthekar Priya, Verhaak Roel, Chalmers Anthony J, Patel Anoop P, Watts Colin, Fecci Peter E, Batchelor Tracy T, Weller Michael, Vogelbaum Michael A, Preusser Matthias, Berger Mitchel S, Khasraw Mustafa
机构信息
The Preston Robert Tisch Brain Tumor Center at Duke, Department of Neurosurgery, Duke University Medical Center, Durham, NC, USA.
Mayo Clinic, Rochester, MN, USA.
出版信息
Nat Med. 2023 Oct;29(10):2402-2405. doi: 10.1038/s41591-023-02464-8.
Abstract
A breakthrough in drug discovery for glioblastoma requires serial collection of tissue from the central nervous system via window of opportunity trials
摘要
胶质母细胞瘤药物研发的突破需要通过机会窗试验从中枢神经系统进行组织的系列采集
相似文献
1
Correcting the drug development paradigm for glioblastoma requires serial tissue sampling.纠正胶质母细胞瘤的药物开发模式需要进行系列组织采样。
Nat Med. 2023 Oct;29(10):2402-2405. doi: 10.1038/s41591-023-02464-8.
2
Therapy for glioblastoma: is it working?胶质母细胞瘤的治疗：有效吗？
Drug Discov Today. 2019 May;24(5):1193-1201. doi: 10.1016/j.drudis.2019.03.008. Epub 2019 Mar 13.
3
[Late and prolonged pseudoprogression in serial posttreatment MRI due to use of new chemotherapy concepts to treat malignant glioblastoma].[使用新的化疗理念治疗恶性胶质母细胞瘤后，系列治疗后MRI出现晚期及持续性假性进展]
Strahlenther Onkol. 2013 Aug;189(8):706-7. doi: 10.1007/s00066-013-0382-6.
4
Repurposing some older drugs that cross the blood-brain barrier and have potential anticancer activity to provide new treatment options for glioblastoma.重新利用一些能够穿过血脑屏障且具有潜在抗癌活性的老药，为胶质母细胞瘤提供新的治疗选择。
Br J Clin Pharmacol. 2016 Feb;81(2):199-209. doi: 10.1111/bcp.12785. Epub 2015 Oct 30.
5
Glioblastoma: Not Just Another Cancer.胶质母细胞瘤：不只是另一种癌症。
Cancer Discov. 2024 Apr 4;14(4):648-652. doi: 10.1158/2159-8290.CD-23-1498.
6
G-protein-coupled receptors as therapeutic targets for glioblastoma.G 蛋白偶联受体作为神经胶质瘤的治疗靶点。
Drug Discov Today. 2021 Dec;26(12):2858-2870. doi: 10.1016/j.drudis.2021.07.008. Epub 2021 Jul 14.
7
Advances in drug development for targeted therapies for glioblastoma.胶质母细胞瘤靶向治疗药物研发进展。
Med Res Rev. 2020 Sep;40(5):1950-1972. doi: 10.1002/med.21676. Epub 2020 May 23.
8
Recent developments in drug delivery strategies for targeting DNA damage response in glioblastoma.近年来针对胶质母细胞瘤中 DNA 损伤反应的药物输送策略的新进展。
Life Sci. 2021 Dec 15;287:120128. doi: 10.1016/j.lfs.2021.120128. Epub 2021 Nov 11.
9
Molecular Mechanisms of Drug Resistance in Glioblastoma.胶质母细胞瘤的耐药分子机制。
Int J Mol Sci. 2021 Jun 15;22(12):6385. doi: 10.3390/ijms22126385.
10
Proteasome inhibition for the treatment of glioblastoma.蛋白酶体抑制剂治疗脑胶质瘤。
Expert Opin Investig Drugs. 2020 Oct;29(10):1133-1141. doi: 10.1080/13543784.2020.1803827. Epub 2020 Aug 10.
引用本文的文献
1
Perioperative IDH inhibition in treatment-naive IDH-mutant glioma: a pilot trial.初治异柠檬酸脱氢酶（IDH）突变型胶质瘤围手术期IDH抑制治疗：一项试点试验
Nat Med. 2025 Aug 21. doi: 10.1038/s41591-025-03884-4.
2
Gabapentinoids confer survival benefit in human glioblastoma.加巴喷丁类药物对人类胶质母细胞瘤有生存获益。
Nat Commun. 2025 May 15;16(1):4483. doi: 10.1038/s41467-025-59614-4.
3
Neoadjuvant triplet immune checkpoint blockade in newly diagnosed glioblastoma.新诊断胶质母细胞瘤的新辅助三联免疫检查点阻断疗法
Nat Med. 2025 May;31(5):1557-1566. doi: 10.1038/s41591-025-03512-1. Epub 2025 Feb 27.
4
A window-of-opportunity trial reveals mechanisms of response and resistance to navtemadlin in patients with recurrent glioblastoma.一项机会窗试验揭示了复发性胶质母细胞瘤患者对纳夫替莫德的反应和耐药机制。
Sci Transl Med. 2025 Feb 19;17(786):eadn6274. doi: 10.1126/scitranslmed.adn6274.
5
Device-assisted strategies for drug delivery across the blood-brain barrier to treat glioblastoma.通过血脑屏障进行药物递送以治疗胶质母细胞瘤的设备辅助策略。
Commun Mater. 2025;6(1):5. doi: 10.1038/s43246-024-00721-y. Epub 2025 Jan 7.
6
A field resource for the glioma cerebrospinal fluid proteome: Impacts of resection and location on biomarker discovery.胶质瘤脑脊液蛋白质组的现场资源：切除和位置对生物标志物发现的影响。
Neuro Oncol. 2025 May 15;27(4):948-962. doi: 10.1093/neuonc/noae277.
7
A hitchhiker's guide to cerebrospinal fluid biomarkers for neuro-oncology.神经肿瘤脑脊液生物标志物指南
Neuro Oncol. 2025 Jun 21;27(5):1165-1179. doi: 10.1093/neuonc/noae276.
8
Functional profiling of murine glioma models highlights targetable immune evasion phenotypes.功能分析揭示了靶向治疗的免疫逃避表型。
Acta Neuropathol. 2024 Nov 27;148(1):74. doi: 10.1007/s00401-024-02831-w.
9
Immune checkpoint inhibitors for glioblastoma: emerging science, clinical advances, and future directions.胶质母细胞瘤的免疫检查点抑制剂：新兴科学、临床进展及未来方向。
J Neurooncol. 2025 Feb;171(3):531-547. doi: 10.1007/s11060-024-04881-2. Epub 2024 Nov 21.
10
Vagus nerve stimulation: Novel concept for the treatment of glioblastoma and solid cancers by cytokine (interleukin-6) reduction, attenuating the SASP, enhancing tumor immunity.迷走神经刺激：通过降低细胞因子（白细胞介素-6）、减弱衰老相关分泌表型、增强肿瘤免疫来治疗胶质母细胞瘤和实体癌的新概念。
Brain Behav Immun Health. 2024 Sep 17;42:100859. doi: 10.1016/j.bbih.2024.100859. eCollection 2024 Dec.
本文引用的文献
1
Prognostic validation of a new classification system for extent of resection in glioblastoma: A report of the RANO resect group.新胶质母细胞瘤切除范围分类系统的预后验证： RANO 切除组报告。
Neuro Oncol. 2023 May 4;25(5):940-954. doi: 10.1093/neuonc/noac193.
2
Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement.胶质母细胞瘤临床试验：现状与改进机遇。
Clin Cancer Res. 2022 Feb 15;28(4):594-602. doi: 10.1158/1078-0432.CCR-21-2750.
3
Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology.中枢神经系统癌症，第 3.2020 版，NCCN 肿瘤学临床实践指南。
J Natl Compr Canc Netw. 2020 Nov 2;18(11):1537-1570. doi: 10.6004/jnccn.2020.0052.
4
The histological representativeness of glioblastoma tissue samples.脑胶质母细胞瘤组织样本的组织代表性。
Acta Neurochir (Wien). 2021 Jul;163(7):1911-1920. doi: 10.1007/s00701-020-04608-y. Epub 2020 Oct 21.
5
Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial.纳武利尤单抗对比贝伐珠单抗治疗复发性胶质母细胞瘤患者的效果：CheckMate 143 期随机临床试验。
JAMA Oncol. 2020 Jul 1;6(7):1003-1010. doi: 10.1001/jamaoncol.2020.1024.
6
Mechanisms and therapeutic implications of hypermutation in gliomas.胶质母细胞瘤中突变的机制及治疗意义。
Nature. 2020 Apr;580(7804):517-523. doi: 10.1038/s41586-020-2209-9. Epub 2020 Apr 15.
7
Phase 0 Trial of AZD1775 in First-Recurrence Glioblastoma Patients.首次复发胶质母细胞瘤患者中 AZD1775 的零期试验。
Clin Cancer Res. 2018 Aug 15;24(16):3820-3828. doi: 10.1158/1078-0432.CCR-17-3348. Epub 2018 May 24.
8
PARADIGM-2: Two parallel phase I studies of olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, with treatment stratified by MGMT status.PARADIGM - 2：两项针对新诊断胶质母细胞瘤患者的奥拉帕利与放疗，或奥拉帕利、放疗联合替莫唑胺的平行I期研究，治疗按MGMT状态分层。
Clin Transl Radiat Oncol. 2017 Nov 21;8:12-16. doi: 10.1016/j.ctro.2017.11.003. eCollection 2018 Jan.
9
The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood-Brain Barrier in Glioblastoma.Wee1抑制剂MK-1775与替莫唑胺联合使用的疗效受胶质母细胞瘤中血脑屏障异质性分布的限制。
Clin Cancer Res. 2015 Apr 15;21(8):1916-24. doi: 10.1158/1078-0432.CCR-14-2588. Epub 2015 Jan 21.
10
Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma.单细胞 RNA 测序凸显原发性脑胶质瘤肿瘤内异质性。
Science. 2014 Jun 20;344(6190):1396-401. doi: 10.1126/science.1254257. Epub 2014 Jun 12.
Zotero 插件